51.05
-0.88 (-1.69%)
| Penutupan Terdahulu | 51.93 |
| Buka | 52.37 |
| Jumlah Dagangan | 526,527 |
| Purata Dagangan (3B) | 933,520 |
| Modal Pasaran | 2,988,681,472 |
| Harga / Pendapatan (P/E Ke hadapan) | 333.33 |
| Harga / Jualan (P/S) | 5.24 |
| Harga / Buku (P/B) | 6.99 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -13.68% |
| Margin Operasi (TTM) | -4.34% |
| EPS Cair (TTM) | -1.35 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 21.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.53% |
| Nisbah Semasa (MRQ) | 1.77 |
| Aliran Tunai Operasi (OCF TTM) | 14.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 86.61 M |
| Pulangan Atas Aset (ROA TTM) | -3.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -17.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Inari Medical, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 8.54% |
| % Dimiliki oleh Institusi | 95.51% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vestal Point Capital, Lp | 30 Sep 2024 | 1,550,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 75.00 (Oppenheimer, 46.92%) | Beli |
| Median | 67.00 (31.24%) | |
| Rendah | 52.00 (Piper Sandler, 1.86%) | Pegang |
| Purata | 66.20 (29.68%) | |
| Jumlah | 3 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 51.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 18 Dec 2024 | 63.00 (23.41%) | Pegang | 55.03 |
| 29 Oct 2024 | 50.00 (-2.06%) | Pegang | 49.18 | |
| Oppenheimer | 17 Dec 2024 | 75.00 (46.91%) | Beli | 56.16 |
| Baird | 29 Oct 2024 | 67.00 (31.24%) | Beli | 49.18 |
| Canaccord Genuity | 29 Oct 2024 | 74.00 (44.96%) | Beli | 49.18 |
| Piper Sandler | 29 Oct 2024 | 52.00 (1.86%) | Pegang | 49.18 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |